Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.57 |
| ▸ | APP | P05067 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.50 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | F7 | P08709 | 1/20 | 0.49 |
| ▸ | F3 | P13726 | 1/20 | 0.49 |
| ▸ | SARM1 | Q6SZW1 | 1/20 | 0.49 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.49 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.49 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.49 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.49 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.49 |
| ▸ | SIRT4 | Q9Y6E7 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1866703 | 0.93 | ALDH1A1 (0.57) | ALDH1A1APPGAAHCAR3HCAR2 | |
| SCHEMBL13580045 | 0.90 | ALDH1A1 (0.57) | ALDH1A1APPGAAHCAR3HCAR2 | |
| Inositol Niacinate SCHEMBL122590 | 0.90 | ALDH1A1 (0.65) | ALDH1A1APPGAAHCAR3HCAR2 | |
| Inositol Niacinate SCHEMBL13557040 | 0.90 | ALDH1A1 (0.65) | ALDH1A1APPGAAHCAR3HCAR2 | |
| Inositol Niacinate SCHEMBL122591 | 0.90 | ALDH1A1 (0.65) | ALDH1A1APPGAAHCAR3HCAR2 | |
| Inositol Niacinate SCHEMBL29499769 | 0.90 | ALDH1A1 (0.65) | ALDH1A1APPGAAHCAR3HCAR2 | |
| SCHEMBL16869481 | 0.90 | ALDH1A1 (0.58) | ALDH1A1APPGAAHCAR3HCAR2 | |
| SCHEMBL14535107 | 0.83 | ALDH1A1 (0.57) | ALDH1A1APPGAAHCAR3HCAR2 | |
| SCHEMBL27105233 | 0.81 | ALDH1A1 (0.54) | ALDH1A1APPGAAHCAR3HCAR2 | |
| SCHEMBL3856644 | 0.78 | LGALS9 (0.55) | ALDH1A1GAAKMT2ALMNATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 977 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12605345-B2 | Transdermal drug delivery system | BioPhysics Pharma, Inc. (US) | 2026-04-21 | — | — | US | claimed |
| US-20250268841-A1 | Trans-Epithelial Membrane Drug Delivery System | Masiz, John J. (US) | 2025-08-28 | — | — | US | claimed |
| US-20250262233-A1 | COMPOSITION | SpecNova LLC (US) | 2025-08-21 | — | — | US | claimed |
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| US-20250120907-A1 | Transmucosal Drug Delivery System | Masiz, John J. (US) | 2025-04-17 | — | — | US | claimed |
| CN-119792539-A | Medicine carrier based on gallic acid-vitamin E polyethylene glycol succinate, micelle, preparation method and application thereof | 上海市第一人民医院 | 2025-04-11 | — | — | CN | claimed |
| CN-119792545-A | Pharmaceutical carrier, micelle, anti-inflammatory and/or anti-atherosclerosis pharmaceutical preparation, and preparation method and application thereof | 上海市第一人民医院 | 2025-04-11 | — | — | CN | claimed |
| US-12246098-B2 | Trans-epithelial membrane drug delivery system | BioPhysics Pharma, Inc. (US) | 2025-03-11 | — | — | US | claimed |
| CN-119139248-A | Preparation process of inositol nicotinate tablet | 吉林显锋科技制药有限公司 | 2024-12-17 | — | — | CN | claimed |
| CN-118873522-A | Application of isothiocyanate compound | 无锡杰西医药股份有限公司 | 2024-11-01 | — | — | CN | claimed |
| WO-2006136402-A1 | THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS | DEVELOGEN AKTIENGESELLSCHAFT (DE) | 2006-12-28 | — | — | WO | claimed |
| CN-1282747-C | Preparation method of inositol nicotinate by enzyme method | UNIV SOUTH CHINA TECH (CN) | 2006-11-01 | — | — | CN | claimed |
| WO-2006066937-A2 | MNK1 OR MNK2 INHIBITORS | DEVELOGEN AKTIENGESELLSCHAFT (DE) | 2006-06-29 | — | — | WO | claimed |
| CN-1546676-A | Preparation method of inositol nicotinate by enzyme method | 华南理工大学 | 2004-11-17 | — | — | CN | claimed |
| CN-1494410-A | Anhydrous antiperspirant and deodorant compositions containing solid, water-soluble, skin active agent | — | 2004-05-05 | — | — | CN | claimed |
| WO-2000010610-A2 | DRUG TARGETING | THERAMARK LIMITED (GB) | 2000-03-02 | — | — | WO | claimed |
| EP-0900563-A1 | Production of pharmaceutical formulations containing aescin for treatment of edema and venous disorders | Klinge Pharma GmbH (DE) | 1999-03-10 | — | — | EP | claimed |
| CN-1034551-C | New use of nicotinic acid and its derivative | QIU BOLING (CN) | 1997-04-16 | — | — | CN | claimed |
| EP-0152106-B1 | ANTIRHEUMATIC COMPOSITIONS | Ismail, Roshdy, Dr. (DE) | 1991-09-25 | — | — | EP | claimed |
| EP-0151987-B1 | MEANS FOR THE TREATMENT OF DISEASES OF THE VEINS AND THE ANAL REGION | Ismail, Roshdy, Dr. (DE) | 1991-05-29 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250262233-A1 | COMPOSITION | GNG2, DSTN, PRSS12 | ALDH1A1 4205/4885APP 3210/4885GAA 1108/4885 |
| US-12605345-B2 | Transdermal drug delivery system | FABP2, VEGFA, CUTA | ALDH1A1 1105/4885APP 1669/4885GAA 3633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.